GOOD TRADERS FORUM

[powerbattles]

$RVVTF just advertised on Bloomberg TV, in Canada.

https://www.b-tv.com/all-videos/revive-therapeutics-for-rare-disorders-and-infectious-diseases-commercial-15sec

$RVVTF PENDING FDA...IND PHASE3 DRUG TREATMENT FOR COVID-19

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19
https://www.globenewswire.com/news-release/2020/06/30/2055779/0/en/Revive-Therapeutics-Announces-Submission-of-Investigational-New-Drug-Application-IND-with-U-S-FDA-for-Phase-3-Confirmatory-Study-for-Bucillamine-in-COVID-19.html

AMAZING VIDEO! RVVTF being compared to VXRT and CYDY ==>
https://www.proactiveinvestors.co.uk/companies/news/923054/revive-

RVVTF Revive Therapeutics Director Signs Manufacturing Arrangement With Vaxart

https://thedeepdive.ca/revive-therapeutics-director-signs-manufacturing-arrangement-with-vaxart/

A Study of N-acetylcysteine in Patients With COVID-19 Infection. The study researchers think that a medication called N-acetylcysteine can help fight the COVID-19 virus by boosting a type of cell in your immune system that attacks infections. View link bellow:

A Study of N-acetylcysteine in Patients With COVID-19 Infection
https://clinicaltrials.gov/ct2/show/study/NCT04374461

Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC. (N-Acetyl Cysteine (Nac) It's no wonder the FDA gave it the fast track go ahead into phase 3.

On June 30, 2020 Revive has submitted its Investigational New Drug (“IND”) application to FDA for a Phase 3 confirmatory study for Bucillamine as a potential treatment in COVID-19.

An IND application may go into effect 30 days after FDA receives the application. Expected FDA approval on or before August 01, 2020.